Adcetris Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Adcetris market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the rising incidence of Hodgkin lymphoma and ALCL, greater awareness of CD30-positive cancers, the expansion of lymphoma treatment options, improvements in healthcare infrastructure and cancer care, and the adoption of treatments for both first-line and relapsed/refractory cases.

Market growth during the forecast period is driven by increased investment in oncology research, rising demand for precision medicine, expansion into emerging markets, a stronger focus on patient access programs, and ongoing clinical trials aimed at expanding indications. Key trends in the forecast period include the growing adoption of targeted therapies in oncology, broader applications for CD30-positive malignancies, increased healthcare spending and access in emerging markets, advancements in antibody-drug conjugate technologies, and higher demand for personalized cancer treatments.

The increasing prevalence of cancer is projected to drive the growth of the adcetris market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer cases is largely attributed to lifestyle factors, such as poor diet and physical inactivity, increased exposure to environmental pollutants, and advancements in diagnostic methods. Adcetris provides substantial benefits for cancer patients by specifically targeting and binding to CD30-positive cancer cells, delivering potent cytotoxic agents directly to the tumor, improving treatment effectiveness, minimizing systemic side effects, and presenting a promising treatment option for patients with certain types of Hodgkin lymphoma and other CD30-expressing cancers. For example, in January 2023, the American Cancer Society reported that the number of cancer cases in the United States reached 1,958,310, with 609,820 cancer-related deaths. As a result, the growing incidence of cancer is a key factor driving the adcetris market.

A prominent trend in the adcetris market is the focus on developing enhanced antibody-drug conjugates (ADCs) and improved drug delivery systems, including combination therapies. These strategies aim to improve therapeutic efficacy, minimize side effects, and more precisely target cancer cells. Combination therapies involve using two or more therapeutic agents with different mechanisms of action, often in synergy, to boost efficacy, reduce resistance, and enhance patient outcomes, while potentially lowering adverse effects compared to monotherapy. For instance, in October 2023, Takeda Pharmaceutical Company received approval from the European Commission (EC) for the use of ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for treating adults with previously untreated CD30+ Stage III Hodgkin lymphoma. This ADC targets CD30, a key marker in Hodgkin lymphoma. The trial results showed that combining ADCETRIS with AVD significantly improved both modified progression-free survival and overall survival rates compared to standard treatments.

In January 2024, Pfizer Inc. acquired Seagen Inc. for $43 billion. This acquisition aims to strengthen Pfizer's oncology portfolio by incorporating Seagen's innovative ADCs, including Adcetris, to enhance its cancer treatment offerings. The move is designed to drive growth in targeted therapies and accelerate Pfizer's ability to deliver advanced cancer treatments to patients worldwide. Seagen Inc. is a US-based biotechnology firm that markets Adcetris.

Major players operating in the adcetris market are Takeda Pharmaceutical Company Limited; Seagen Inc.

North America was the largest region in the adcetris market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adcetris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the adcetris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) designed to target CD30, a protein present on the surface of certain cancer cells, including those associated with Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It combines a monoclonal antibody with a cytotoxic agent, monomethyl auristatin E (MMAE), enabling targeted chemotherapy delivery to cancer cells, enhancing efficacy while minimizing off-target side effects.

The primary forms of adcetris are powder and liquid. It is provided as a sterile, white to off-white lyophilized powder in single-dose vials. Before administration, healthcare providers reconstitute the powder with a specified amount of sterile water to prepare it for intravenous infusion. Its indications include Hodgkin lymphoma, systemic anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, and others. Adcetris is utilized in various settings, such as hospitals, drug stores, and more.

The adcetris market research report is one of a series of new reports that provides adcetris market statistics, including adcetris industry global market size, regional shares, competitors with a adcetris market share, detailed adcetris market segments, market trends, and opportunities, and any further data you may need to thrive in the adcetris industry. This adcetris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adcetris market consists of sales of brentuximab vedotin-based therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors for the treatment of lymphoma and related cancers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.